Istanbul University Faculty of Medicine. Sports Medicine Department
Istanbul, 34093, Turkey (Türkiye)
NCT Number: NCT06912919
Participants will be selected from sedentary men aged 18-30 and over with a body mass index of 25. First, an informed consent form will be signed by the individuals. The 'International Physical Activity Questionnaire' will be applied to the participants and it will be ensured that the participants have not participated in vigorous and moderate activities and therefore are inactive or minimally active individuals. The study will consist of an intervention group and a control group, and the groups will be randomized via computer. The exclusion criteria of the study are that the participants do not have any known cardiac or pulmonary pathology and do not have any musculoskeletal disorders that will affect their participation in exercise. First, blood samples will be taken from the participants. They will be sent to the laboratory for examination of biochemical, hormonal and antioxidant parameters. Then, the muscle cross-sectional area and muscle thickness values of the rectus femoris muscle will be calculated from the participants with ultrasound measurements. After these procedures are completed, Vo2Max calculation will be performed on the participants with a cardiopulmonary exercise test. In addition, 40% of the Vo2Max value calculated in this test will be calculated and the pulse range to be used in the exercise will be determined. In the final stage, participants' strength isokinetic test and knee flexion extension strength and endurance values will be calculated.
After the evaluations are completed, individuals will start a 6-week exercise program. The intervention group will exercise with the blood flow restriction method under 160 mmHg pressure for the first 3 weeks and 180 mmHg pressure for the last 3 weeks. The device will be applied by placing it at the most proximal point of the thigh. The control group will do the same exercise without restricting blood flow. Both groups will be followed for 6 weeks with a 5-minute warm-up followed by a 20-minute exercise program. Participants will report their fatigue with the Borg scale after each exercise session.
After the exercise sessions are completed, blood will be taken on an empty stomach within 24 hours of the last exercise. Then, muscle size measurement with ultrasound, Vo2Max calculation and isokinetic test power calculation will be noted, respectively. The values obtained will be compared with the initial values.
Looking for future studies?
Notify Me18 year–30 year
Male
Interventional
Not applicable
Istanbul, 34093, Turkey (Türkiye)
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Age: 18-30 Gender: Male Body Mass Index (BMI) ≥ 25 kg/m² Inactive or minimally active individuals (assessed with the International Physical Activity Questionnaire - IPAQ) No history of metabolic, cardiovascular or neuromuscular disease Not taking any medication that affects metabolism, hormones or muscle function Able to participate in a 6-week exercise program
Exclusion criteria
Having a cardiac or respiratory complaint Having a known chronic disease Having a medication used regularly
Low-intensity cycling exercise with BFR (pressure of 160-180 mmHg) for 20 minutes, 3 days a week for 6 weeks.
Low-intensity cycling exercise (without BFR) for 20 minutes, 3 days a week for 6 weeks.
Time frame: 6 weeks (pre-post test)
VO2Max (ml/kg/min) will be measured by indirect gas analysis and compared before and after exercise.
Time frame: 6 weeks (pre-post test)
Quadriceps and hamstring strength will be evaluated with an isokinetic dynamometer.
Time frame: 6 weeks (pre-post test)
The muscle cross-sectional area (cm²) of the Rectus Femoris will be measured by ultrasound (USG) and its change will be evaluated.
Time frame: 6 weeks (pre-post test)
The muscle thickness (mm) of the Rectus Femoris will be measured by ultrasound (USG) and its change will be evaluated.
Time frame: 6 weeks
Systemic oxidative stress and total antioxidant capacity will be assessed through blood biomarkers before and after the intervention.
Time frame: 6 weeks
Cortisol levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Glucose levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Creatine kinase levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Cholesterol levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Triglyceride levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Blood samples will be collected to measure testosterone levels before and after the intervention.
Time frame: 6 weeks
Luteinizing hormone (LH) levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Follicle-stimulating hormone (FSH) levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Dehydroepiandrosterone sulphate (DHEAS) levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Sex hormone-binding globulin (SHBG) levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Free androgen index (FAI) levels will be measured with a pre- and post-exercise blood test.
Time frame: 6 weeks
Istanbul University
Other
Acronym: YT BFR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07009171
Body Weight, Nutrition Disorders
Suwon, Gyeonggi-do, South Korea
View Trial DetailsNCT06892587
Body Weight, Nutrition Disorders
Fort Collins, Colorado, United States
View Trial DetailsNCT06771986
Body Weight, Nutrition Disorders
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT05391958
Body Weight, Digestive System Diseases
Qinhuangdao, China
View Trial Details